MedTrace Logo

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

NCT01999361 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-03-23

No results posted yet for this study

Summary

This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

Myfortic

treatment with myfortic

Sponsors & Collaborators

  • Rodolfo Alejandro

    lead OTHER

Principal Investigators

  • Rodolfo Alejandro, MD · University of Miami

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2027-01-31
Completion
2028-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01999361 on ClinicalTrials.gov